1215 related articles for article (PubMed ID: 33373368)
1. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
Rao L; Ren C; Luo S; Huang C; Li X
Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
4. The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis.
Li M; Liu Z; Yang X; Zhang J; Han M; Zhang Y; Liu Y
J Diabetes Complications; 2023 Dec; 37(12):108632. PubMed ID: 37907042
[TBL] [Abstract][Full Text] [Related]
5. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
Lin DS; Lee JK; Chen WJ
J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Liu J; Li L; Li S; Wang Y; Qin X; Deng K; Liu Y; Zou K; Sun X
Diabetes Obes Metab; 2020 Sep; 22(9):1619-1627. PubMed ID: 32364674
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
Edwards K; Li X; Lingvay I
J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study.
Silva VB; Fonseca L; Duarte DB; Puga FM; Assuncao G; Garrido S; Teixeira S; Vilaverde J; Cardoso MH
Endocr Regul; 2023 Jan; 57(1):144-151. PubMed ID: 37561831
[No Abstract] [Full Text] [Related]
10. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
12. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
13. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Li K; Xu G
J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
[TBL] [Abstract][Full Text] [Related]
15. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
16. [SGLT 2 inhibitors in Type 1 diabetes].
Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
18. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
Zhou Y; Wang FR; Wen FF; Li C; Ye TT
Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
